Provided by Tiger Trade Technology Pte. Ltd.

VanEck Healthcare TruSector ETF

28.34
+0.18890.67%
Post-market: 28.430.0935+0.33%16:14 EDT
Volume:140
Turnover:4K
Market Cap:850.10K
PE:- -
High:28.43
Open:28.43
Low:28.34
Close:28.15
52wk High:28.76
52wk Low:24.78
Shares:30.00K
Float Shares:30.00K
Volume Ratio:0.61
T/O Rate:0.47%
Dividend:0.08
Dividend Rate:0.30%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Merck announces initial access plans for alimatravir

TIPRANKS
·
Jul 24

Merck & Co - Signs Seven Voluntary Licensing Agreements with Generic Manufacturers in Africa and India

THOMSON REUTERS
·
Jul 24

Merck & Co - Royalty-free Agreements Enable Supply of Generic Alimatravir in 129 Lmics

THOMSON REUTERS
·
Jul 24

Merck Licenses Experimental HIV Pill to Generic Makers in 129 Countries

Reuters
·
Jul 24

Merck: Voluntary Licensing Agreements for Alimatravir Cover 129 Countries

THOMSON REUTERS
·
Jul 24

Merck: Plans Initial Alimatravir Supply Pending Regulatory Approval, Generic Manufacturing Ramp-up in Licensed Territories

THOMSON REUTERS
·
Jul 24

Merck: Announces Initial Access Plans for Alimatravir in Low- and Middle Income Countries for Prevention of Hiv-1

THOMSON REUTERS
·
Jul 24

Merck: in Active Discussions with Fiocruz on Alimatravir Availability in Latin America & Brazil

THOMSON REUTERS
·
Jul 24

Gilead’s Trodelvy plus Merck’s Keytruda recommended by CHMP in breast cancer

TIPRANKS
·
Jul 24

Ema's Chmp: Recommends Granting Marketing Authorisation for Icotyde

THOMSON REUTERS
·
Jul 24

Novo Nordisk Seeks Preliminary Injunction Against Lilly Weight-loss Ads

Reuters
·
Jul 24

Novo Nordisk: Asked the Court to Preliminarily Halt Eli Lilly's Misleading Glp-1 Advertising Campaigns While Novo Nordisk’s Lawsuit Proceeds

THOMSON REUTERS
·
Jul 24

Stocks to Watch: Intel, Deckers, Edwards Lifesciences, Genmab

Dow Jones
·
Jul 24

Genmab, Abbvie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial

Dow Jones
·
Jul 24

Merck & Co. Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 24

Abbvie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 24

Genmab, Abbvie Clarify Primary Endpoints in Phase 3 Epcore Dlbcl-1 Trial

Reuters
·
Jul 24

Genmab: Clarify Overall Survival (os) was Sole U.S. Primary Endpoint in Phase 3 Epcore(®) Dlbcl-1 Trial and was not Met

THOMSON REUTERS
·
Jul 24

Genmab and Abbvie Provide Clarification on Phase 3 Epcore® Dlbcl-1 Trial Evaluating Epcoritamab (duobody®-cd3xcd20) in Patients with Relapsed/refractory Diffuse Large B-cell Lymphoma (dlbcl)

THOMSON REUTERS
·
Jul 24

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

GlobeNewswire
·
Jul 24